Nurix’s CEO, Arthur T. Sands, M.D., Ph.D., discussed Nurix’s differentiated BTK degraders NX-5948 and NX-2127 and promising new safety and efficacy data that were presented at #ASH2023 with Brad Loncar on BiotechTV. Watch the interview below.
𝐀𝐒𝐇 𝐀𝐧𝐧𝐮𝐚𝐥 𝐌𝐞𝐞𝐭𝐢𝐧𝐠: Talking BTK degraders with Nurix Therapeutics CEO Arthur T. Sands, M.D., Ph.D.. He elaborates on two programs Nurix presented updated data for at #ASH23 and dives into the company's pipeline and partnerships. Full video: https://lnkd.in/gb4rYgeH BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking
CSO Partner @ Curie.Bio | Biotech Venture Creation
10moGood and simple explanations for TPD and how degradation differentiates vs inhibitors.